Clinical trials access remains limited as only 24% of drugs tested in 89 countries are available post-approval.
Browsing: Market Access
Updates on pricing, reimbursement, HTA decisions, and access policies affecting global healthcare markets.
Novo Nordisk Wegovy Pricing launches at $349 per month, months ahead of schedule, impacting the obesity drug market.
Ozempic pricing is under scrutiny as Senator Sanders suggests generic versions could cost under $100/month.
AmgenNow platform enhances direct-to-consumer access, aiming to streamline patient engagement and improve market reach.
Colorado Enbrel payment limit set at $600 per unit, impacting Amgen’s pricing strategy and potentially influencing other states.
Amgen Repatha pricing sees a 60% reduction in the U.S. through a new program, enhancing market access.
Keytruda subcutaneous launch by Merck aims to offset sales decline as original loses patent protection, with analysts projecting market impact.
Crystalys gout drug debuts with $205M funding and partial rights in multiple Asian countries.
Bristol Myers Squibb launches Sotyktu at an 86% discount, reducing the price to $950 for cash-paying U.S. patients.
Trump drug price deadline prompts pharma firms to announce initiatives, impacting U.S. market with new models.